1. Alternative Licensing Solutions for Global Access Open Science Summit: Theme 5: The Role of Universities Rebecca Goulding, PhD ISIS, Sauder School of Business, UBC Intellectual Property and Policy Research Group, UBC [email_address]

3. The Problem

4. Neglected Diseases (ND) Pipeline Gaps Pre- Discovery clinical Clinical Trials Delivery 1. Discovery Gap 2. Research and Development (R&D) Gap 3. Delivery Gap 1 2 2 3

8. The R&D gap Trouiller et al., Lancet 2002 Proportion of DALYS Proportion of new drugs - 1975-1999 0 % 2 % 4 % 6 % 8 % 10 % 12 % 14 % C a r d i o v a s c u l a r C a n c e r H I V / A I D S T u b e r c u l o s i s M a l a r i a T r o p i c a l d i s e a s e s Cardio Cancer HIV TB Malaria Tropical diseases

16. viral open license - use - modify - redistribute open license open license

21. Patent Pools one standard non-exclusive license When two or more patent holders license their IP rights to one another or to a specifically created admin entity, or to a third party.

22. Early patent pools

28. Global Access Licensing License with specific terms/clauses that ensure access to drug/diagnostic etc in developing countries

29. University Principles on Global Access “ Nine Points To Consider…” 2008 2007 2009

32. Various forms of IP and control of invention Public Domain OS Patent + Viral License OS Patent Non-Viral License Patent + Non-exclusive License Patent + Exclusive License Control

33. Access to improvements University Mission Industry Interest NGO/Activists Alumni Journal Requirements Funding Agency Requirements s Students Researchers desire to commercialize Tenure Requirements Researchers desire for openness

34. Thanks!

35. Open Source: Decision Tree